Genmab A/S (OTCMKTS:GNMSF – Get Free Report) will likely be announcing its results after the market closes on Thursday, November 5th. Analysts expect Genmab A/S to post earnings of $3.52 per share and revenue of $1.20 billion for the quarter.
Genmab A/S Stock Up 32.1%
OTCMKTS GNMSF opened at $580.00 on Thursday. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. Genmab A/S has a 52 week low of $232.34 and a 52 week high of $581.00. The firm has a market capitalization of $35.71 billion, a price-to-earnings ratio of 45.49 and a beta of 0.79. The company has a fifty day moving average of $360.98 and a two-hundred day moving average of $302.82.
About Genmab A/S
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Featured Stories
- Five stocks we like better than Genmab A/S
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
